Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 17, 2017 (10 years ago)

Fluocinonide Cream UPS

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Fluocinonide Cream UPS, 0.05% (Emulsified Base), packaged in 60 g tube, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada, Dist. by Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-1254-3

Affected NDC 51672-1254-03

Compare with the code on your package — it is the most precise check available.

Drug: Fluocinonide

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fluocinonide
NDC 51672-1254
.5 mg/g Cream
Topical
Sun Pharmaceutical Industries, Inc. Rx
Recalling firm
Taro Pharmaceuticals U.S.A., Inc.
NDC code
51672-1254-3
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0790-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Fluocinonide recalls

See all
Class II · Moderate risk

Fluocinonide

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1386-3 D-0477-2026
Class II · Moderate risk

Fluocinonide

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1386-2 D-0476-2026
Class II · Moderate risk

Fluocinonide

Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.

Ongoing Failed specification Sun Pharmaceutical Industries INC NDC 51672-1386-1 D-0475-2026
Class II · Moderate risk

Fluocinonide Topical Solution USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 52565-025-20 D-0685-2022
Class II · Moderate risk

Fluocinonide Gel USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 52565-054-15 D-0684-2022

Other recalls by Taro Pharmaceuticals U.S.A., Inc.

All 2017 recalls
Class III · Low risk

Hydrocortisone 1% & Acetic Acid 2% Otic Solution

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Completed Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 51672-3007-01 D-0633-2024